Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans
- PMID: 21430088
- PMCID: PMC3292331
- DOI: 10.2337/db10-0474
Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans
Abstract
Objective: Glucagon-like peptide (GLP)-1 lowers postprandial glycemia primarily through inhibition of gastric emptying. We addressed whether the GLP-1-induced deceleration of gastric emptying is subject to rapid tachyphylaxis and if so, how this would alter postprandial glucose control.
Research design and methods: Nine healthy volunteers (25 ± 4 years old, BMI: 24.6 ± 4.7 kg/m(2)) were examined with intravenous infusion of GLP-1 (0.8 pmol · kg(-1) · min(-1)) or placebo over 8.5 h. Two liquid mixed meals were administered at a 4-h interval. Gastric emptying was determined, and blood samples were drawn frequently.
Results: GLP-1 decelerated gastric emptying significantly more after the first meal compared with the second meal (P = 0.01). This was associated with reductions in pancreatic polypeptide levels (marker of vagal activation) after the first but not the second meal (P < 0.05). With GLP-1, glucose concentrations declined after the first meal but increased after the second meal (P < 0.05). The GLP-1-induced reductions in postprandial insulin and C-peptide levels were stronger during the first meal course (P < 0.05). Likewise, glucagon levels were lowered by GLP-1 after the first meal but increased after the second test meal (P < 0.05).
Conclusions: The GLP-1-induced delay in gastric emptying is subject to rapid tachyphylaxis at the level of vagal nervous activation. As a consequence, postprandial glucose control by GLP-1 is attenuated after its chronic administration.
Figures
Similar articles
-
Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.Diabetes. 2005 Jul;54(7):2212-8. doi: 10.2337/diabetes.54.7.2212. Diabetes. 2005. PMID: 15983224
-
The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans.Am J Physiol Endocrinol Metab. 2006 Jun;290(6):E1118-23. doi: 10.1152/ajpendo.00576.2005. Epub 2006 Jan 10. Am J Physiol Endocrinol Metab. 2006. PMID: 16403774
-
Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.Am J Physiol. 1997 Nov;273(5):E981-8. doi: 10.1152/ajpendo.1997.273.5.E981. Am J Physiol. 1997. PMID: 9374685 Clinical Trial.
-
Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying--preclinical evidence.J Diabetes Complications. 2014 Jan-Feb;28(1):110-4. doi: 10.1016/j.jdiacomp.2013.06.003. Epub 2013 Aug 28. J Diabetes Complications. 2014. PMID: 23992745 Review.
-
The role of gastric emptying in glucose homeostasis and defense against hypoglycemia: Innocent bystander or partner in crime?Diabetes Res Clin Pract. 2023 Sep;203:110828. doi: 10.1016/j.diabres.2023.110828. Epub 2023 Jul 20. Diabetes Res Clin Pract. 2023. PMID: 37481116 Review.
Cited by
-
Safe Continuation of Glucagon-like Peptide 1 Receptor Agonists at Endoscopy: A Case Series of 57 Adults Undergoing Endoscopic Sleeve Gastroplasty.Obes Surg. 2024 Jul;34(7):2369-2374. doi: 10.1007/s11695-024-07278-2. Epub 2024 May 16. Obes Surg. 2024. PMID: 38753265
-
Glucagon-Like Peptide-1 Agonists and General Anesthesia: Perioperative Considerations and the Utility of Gastric Ultrasound.Cureus. 2024 Apr 11;16(4):e58042. doi: 10.7759/cureus.58042. eCollection 2024 Apr. Cureus. 2024. PMID: 38738030 Free PMC article. Review.
-
Targeting the incretin system in obesity and type 2 diabetes mellitus.Nat Rev Endocrinol. 2024 Aug;20(8):447-459. doi: 10.1038/s41574-024-00979-9. Epub 2024 Apr 17. Nat Rev Endocrinol. 2024. PMID: 38632474 Review.
-
Practical guide: Glucagon-like peptide-1 and dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists in diabetes mellitus.World J Diabetes. 2024 Mar 15;15(3):331-347. doi: 10.4239/wjd.v15.i3.331. World J Diabetes. 2024. PMID: 38591071 Free PMC article. Review.
-
Effectiveness and safety of glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes: evidence from a retrospective real-world study.Front Endocrinol (Lausanne). 2024 Mar 8;15:1347684. doi: 10.3389/fendo.2024.1347684. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38524632 Free PMC article.
References
-
- Meier JJ, Nauck MA. Glucagon-like peptide 1 (GLP-1) in biology and pathology. Diabetes Metab Res Rev 2005;21:91–117 - PubMed
-
- Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003;26:2929–2940 - PubMed
-
- Holst JJ. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors. Expert Opin Emerg Drugs 2004;9:155–166 - PubMed
-
- Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741–744 - PubMed
-
- Meier JJ, Gallwitz B, Salmen S, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 2003;88:2719–2725 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous